Clinical trial
A Study of Cinacalcet to Improve Achievement of National Kidney Foundation…
NCT00431496 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00431496 |
|---|---|
| Title | A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Targets in Patients With End Stage Renal Disease (ESRD) |
| Official title | A Study To Assess Achievement of NKF K/DOQI Targets Using Sensipar (Cinacalcet) in Australian Subjects With End Stage Renal Disease (ESRD) Who Are Being Treated With Aranesp for Anaemia Management |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Anemia, Secondary Hyperparathyroidism |
| Intervention type | Drug |
| Interventions | Cinacalcet |
| Enrollment | 71 |
| Start date | Sep 1, 2006 |
| Primary completion | Jun 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Feb 5, 2007 |
| Last update posted | Apr 24, 2013 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: